tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

NTLA Stock Latest News

Promising Phase 1 Results and High Interest in Phase 3 Trial Boost Buy Rating for Intellia Therapeutics
RatingsPromising Phase 1 Results and High Interest in Phase 3 Trial Boost Buy Rating for Intellia Therapeutics
9d ago
NTLA
Intellia Therapeutics Announces Positive Phase 1 Trial Data
PremiumCompany Announcements
Intellia Therapeutics Announces Positive Phase 1 Trial Data
10d ago
8K
NTLA
Intellia Therapeutics’ Lonvo-z Shows Promising Efficacy and Safety, Supporting Buy Rating
PremiumRatings
Intellia Therapeutics’ Lonvo-z Shows Promising Efficacy and Safety, Supporting Buy Rating
10d ago
NTLA
Intellia Therapeutics’ NTLA-2002 Shows Promising Efficacy and Safety in HAE Treatment, Supporting Buy Rating
PremiumRatings
Intellia Therapeutics’ NTLA-2002 Shows Promising Efficacy and Safety in HAE Treatment, Supporting Buy Rating
10d ago
NTLA
Intellia’s Lonvo-z: Promising Phase 1 Results Amid Market Competitiveness and Safety Concerns
PremiumRatings
Intellia’s Lonvo-z: Promising Phase 1 Results Amid Market Competitiveness and Safety Concerns
10d ago
NTLA
Intellia Therapeutics: Expert Confidence in Addressing Liver Enzyme Concerns Supports Buy Rating
PremiumRatingsIntellia Therapeutics: Expert Confidence in Addressing Liver Enzyme Concerns Supports Buy Rating
13d ago
NTLA
Intellia Therapeutics Holds Annual Stockholders’ Meeting
Premium
Company Announcements
Intellia Therapeutics Holds Annual Stockholders’ Meeting
14d ago
8K
NTLA
Intellia Therapeutics price target lowered to $54 from $74 at Canaccord
Premium
The Fly
Intellia Therapeutics price target lowered to $54 from $74 at Canaccord
23d ago
NTLA
Cathie Wood’s ARK Investment buys 226K shares of Intellia Therapeutics today
PremiumThe Fly
Cathie Wood’s ARK Investment buys 226K shares of Intellia Therapeutics today
26d ago
NTLA
Positive Outlook on Intellia Therapeutics Despite Mild Adverse Event in Phase 3 Study
PremiumRatings
Positive Outlook on Intellia Therapeutics Despite Mild Adverse Event in Phase 3 Study
27d ago
NTLA
Intellia Therapeutics: Positive Outlook and Strong Enrollment Support Buy Rating
PremiumRatings
Intellia Therapeutics: Positive Outlook and Strong Enrollment Support Buy Rating
27d ago
NTLA
Intellia’s Phase 3 Programs Progress Unhindered Despite Safety Concerns
PremiumRatings
Intellia’s Phase 3 Programs Progress Unhindered Despite Safety Concerns
27d ago
NTLA
Cathie Wood’s ARK Investment buys 201K shares of Intellia Therapeutics today
PremiumThe FlyCathie Wood’s ARK Investment buys 201K shares of Intellia Therapeutics today
28d ago
NTLA
Court blocks Trump tariffs, Musk steps away from DOGE: Morning Buzz
Premium
The Fly
Court blocks Trump tariffs, Musk steps away from DOGE: Morning Buzz
28d ago
S
AI
Intellia Therapeutics Faces Safety and Efficacy Challenges with Nex-Z: Analyst Issues Sell Rating
Premium
Ratings
Intellia Therapeutics Faces Safety and Efficacy Challenges with Nex-Z: Analyst Issues Sell Rating
28d ago
NTLA
Intellia commercial position in question after safety event. says Goldman
PremiumThe Fly
Intellia commercial position in question after safety event. says Goldman
28d ago
NTLA
Intellia Therapeutics price target lowered to $39 from $43 at BofA
PremiumThe Fly
Intellia Therapeutics price target lowered to $39 from $43 at BofA
28d ago
NTLA
Intellia adverse event could resurface questions, says JPMorgan
PremiumThe Fly
Intellia adverse event could resurface questions, says JPMorgan
28d ago
NTLA
Intellia discloses grade 4 liver transaminase elevation in MAGNITUDE trial
PremiumThe Fly
Intellia discloses grade 4 liver transaminase elevation in MAGNITUDE trial
28d ago
NTLA
Positive Outlook for Intellia Therapeutics Despite Safety Concerns in MAGNITUDE Trial
PremiumRatingsPositive Outlook for Intellia Therapeutics Despite Safety Concerns in MAGNITUDE Trial
28d ago
NTLA
Intellia Therapeutics: Buy Rating Affirmed Despite Safety Concerns in MAGNITUDE Study
Premium
Ratings
Intellia Therapeutics: Buy Rating Affirmed Despite Safety Concerns in MAGNITUDE Study
28d ago
NTLA
Closing Bell Movers: Nvidia gains 4% on earnings, lifting other semis
Premium
The Fly
Closing Bell Movers: Nvidia gains 4% on earnings, lifting other semis
29d ago
A
S

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >